PMC10018749_01
(A) Bone age z-scores plotted against chronological age throughout the course of treatment. (B) Height z-scores corrected for bone age plotted against chronological age throughout the course of treatment. (C) Heights plotted throughout course of treatment over the standardized pediatric growth chart as published by the CDC. Initiation and termination of anastrozole treatment is indicated with arrows.
fendo-14-1101843-g001.jpg
PMC10018749_01_fendo-14-1101843-g001.jpg
f1
Overall, her bone ages, which were monitored every 6-12 months, gradually normalized following the initiation of anastrozole treatment and showed little interval maturation thereafter. ( Table 1 ) ( Figure 1A ). Eventually, she achieved an adult height of 180.3 cm (height z-score, 2.3) compared to a mid-parental height of 176.5 cm (target height z-score, 2.0) ( Table 1 ) ( Figures 1B,C ).
FSH, LH, D4A, 17-OHP, and testosterone concentrations over the course of treatment. Initiation and termination of treatment are indicated with colored arrows. D4A, androstenedione; 17-OHP, 17-hydroxyprogesterone. Initiation and termination of anastrozole treatment is indicated with arrows.
fendo-14-1101843-g002.jpg
PMC10018749_01_fendo-14-1101843-g002.jpg
f2
Ongoing monitoring during treatment included adrenal steroid levels and liver transaminases, both of which stable throughout the course of treatment. ( Figure 2 ).